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 2 
SUMMARY 31 
 32 
Setting: The study took place in Cape Town, South Africa from 2010-2013 as part of an 33 
observational cohort in 10 primary health facilities. 34 
Study Aim: A comparison of costs incurred by patients in MDRTBPlus line probe assay and Xpert 35 
MTB/RIF-based diagnostic algorithms, from the onset of illness until multidrug-resistant 36 
tuberculosis treatment initiation.  37 
Methods: Eligible patients were identified from laboratory and facility records, interviewed 3-6 38 
months after treatment initiation and a cost questionnaire completed. Direct and indirect costs, 39 
individual and household income, loss of individual income and change in household income 40 
were recorded in local currency, adjusted to 2013 costs and converted to US$. 41 
Results: The median number of visits to initiation of multidrug-resistant tuberculosis treatment 42 
was reduced from 20 to 7 (p<0.001) and median costs from $68.1 to $38.3 (p=0.004) in the 43 
Xpert group. From the onset of symptoms to being interviewed, the proportion unemployed 44 
increased from 39% to 73% in the LPA group (p<0.001) and from 53% to 89% in the Xpert 45 
group (p<0.001). There was a decrease of 16% in median household income in the LPA group 46 
and 13% in the Xpert group. 47 
Conclusion: The introduction of an Xpert-based algorithm brought relief by decreasing the cost 48 
incurred by patients, but the loss of employment and income persist. Patients require support to 49 
mitigate this impact. 50 
 51 
 52 
Key words: molecular diagnostic tests, patient costs, income loss, impact assessment.  53 
 54 
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BACKGROUND 56 
"TB is the child of poverty - and also its parent and provider" [Archbishop Desmond Tutu.] 57 
 58 
Tuberculosis (TB) disproportionately affects the poor(1) due to a complex interaction between 59 
many factors, including, poor nutrition, overcrowded living or working conditions, and 60 
concomitant disease, such as human immunodeficiency virus (HIV) infection(2,3). TB 61 
perpetuates a cycle of poverty with affected families losing household income through disability 62 
or death and confronting costs in diagnosing and treating the disease. TB also affects the most 63 
economically viable, being among the top three causes of death for women aged 15 - 44 years(4).  64 
 65 
TB patients incur significant costs from the onset of their illness until diagnosis, with costs, as a 66 
percentage of household income, being higher for poor patients(5–9). Long delays exist between 67 
the onset of TB symptoms and initiation of TB treatment, attributed to both the patient and the 68 
health system(10,11). The longer this delay, the more likely a patient is to both transmit TB(12) 69 
and to incur costs for  transport, accessing healthcare, purchasing pharmaceuticals, and losing 70 
work time and productivity.  71 
 72 
Several systematic reviews report on diagnostic and treatment costs faced by TB patients. Costs 73 
ranged widely between countries with one review reporting the largest costs being incurred for 74 
hospitalization, medication, transportation and private healthcare(6). Ukwaja et al(13) report 75 
mean diagnostic costs for patients in Africa ranging between 10.4% to 35% of mean annual 76 
income and concluded that average diagnostic costs for TB were “catastrophic”, defined in 77 
different studies as costs greater than 10% of monthly or annual household income, greater than 78 
40% of non-subsistence household income, or the use of non-reversible coping strategies (5,14). 79 
Patients in the lowest income bracket face the greatest risk of “catastrophic” costs(5). Tanimura 80 
et al(14) found that direct medical costs accounted on average for 20%, direct non-medical costs 81 
for 20% and income loss for 60% of total cost for patients in low- and middle-income countries. 82 
Pre-treatment costs accounted for half of total costs. In Burkina Faso, 72% of patients were 83 
found to have incurred direct medical costs during the pre-diagnostic phase(15).  84 
 85 
Those with multi-drug resistant (MDR) TB face an even greater economic burden, with low cure 86 
rates and lengthy treatment of up to two years(16–18).  Three studies reported by Tanimura et 87 
al disaggregated the total costs for TB and MDR-TB patients and showed that costs were higher 88 
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for those with MDR-TB(14). In one of these studies pre-diagnostic costs for MDR-TB patients 89 
were just over double that of TB patients(17). No studies from sub-Saharan Africa were found 90 
pertaining specifically to MDR-TB patient diagnostic costs. 91 
 92 
Implementation of Xpert MTB/RIF (Xpert) has reduced the time taken to diagnose MDR-TB(19)  93 
and it is anticipated that patients will benefit economically through fewer pre-treatment 94 
healthcare visits, and the potential for an earlier diagnosis to decrease morbidity and mortality. 95 
It is important to ascertain the benefit which new technology affords to vulnerable groups(20). 96 
This study compared costs incurred by patients in MDRTBPlus line probe assay (LPA) and Xpert-97 
based diagnostic algorithms, from the onset of symptoms until MDR-TB treatment initiation. 98 
 99 
METHODS 100 
 101 
Setting:  102 
 103 
The study took place in a routine operational setting in Cape Town, South Africa. The country has 104 
high levels of poverty, with 56.8% of people living below the poverty line(21). Household 105 
incomes show persistent disparities along racial lines, with average annual household income of 106 
ZAR387,011 amongst “white” households compared to ZAR 69,632 amongst “black” households 107 
and 48.7% of “black” households with annual household income <ZAR9,886(22). The 108 
government has implemented a range of social protection measures to combat this, including 109 
both conditional (child support and disability grants) and unconditional (pensions for men >65 110 
and women >60-years old) cash transfers and the provision of free primary health services (23). 111 
 112 
Free TB diagnostic services were provided at 142 primary health-care (PHC) facilities in Cape 113 
Town; 101 of these together with the dedicated TB–hospital offered free TB treatment. There 114 
was a PHC facility within about a 5 km radius of all households.  TB tests were done at a central 115 
laboratory and results recorded in an electronic laboratory database. 116 
 117 
In 2010, a smear, culture and LPA-based diagnostic algorithm was in place (Figure 1) with LPA 118 
performed on culture isolates in high MDR-risk TB presumptive cases. From 2011 Xpert was 119 
sequentially introduced into facilities, replacing smear microscopy for all presumptive TB cases 120 
(Figure 1). In both algorithms, cases with a failing 1st line TB treatment regimen were evaluated 121 
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for MDR-TB through culture and LPA. We refer to patients diagnosed under these algorithms as 122 
the LPA and Xpert groups respectively.   123 
 124 
MDR-TB patients received standardised treatment regimens. At the start of data collection in 125 
2010, doctors at the TB hospital reviewed case records and prescribed treatment but most 126 
patients initiated treatment at PHC facilities. Since 2012 (mid-way through the study), doctors 127 
could initiate MDR-TB treatment at PHC facilities without the need for prior review of case 128 
records at the TB-hospital.  129 
 130 
Study Population:  131 
 132 
The study was part of an observational cohort in 10 high TB-burden PHC facilities selected from 133 
a total of 29 that met the criteria of a TB caseload of >350 in 2009. We sorted facilities from best 134 
to worst performing based on new smear positive treatment outcomes and randomly selected 135 
five facilities above and five below the median treatment success rate of 78%. 136 
 137 
Eligible patients diagnosed in either algorithm were >18-years of age, had been diagnosed with 138 
rifampicin or rifampicin and isoniazid resistance from sputa tested in Cape Town between June 139 
2010 and December 2012, and had received MDR-TB treatment at one of the 10 PHC facilities. 140 
Patients with previous MDR-TB treatment were excluded, as their pathway to care may have 141 
been different. Those with pre- or extensively drug-resistant TB or who had interrupted MDR-TB 142 
treatment at the time of the scheduled interview were excluded.  For infection control and safety 143 
of the researchers, only patients who had been on MDR-TB treatment for at least 3 months and 144 
were smear negative were interviewed. 145 
 146 
Data Sources and Collection: 147 
 148 
Patients diagnosed at selected facilities were identified from the electronic laboratory database; 149 
those diagnosed elsewhere, but on treatment at selected facilities, were identified from facility 150 
DR-TB paper registers and clinical records.  151 
 152 
Trained professional nurses located patient folders, reviewed study eligibility and recorded 153 
demographic, laboratory and clinical data, and the patients’ healthcare visits on case report 154 
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forms. The clinical coordinator used this information to populate a timeline on a patient cost 155 
questionnaire with the number and dates of visits. This was used to probe and clarify responses 156 
provided by the patient during the interview. 157 
 158 
Three to six months after the start of treatment, one of two graduate social scientists obtained 159 
informed consent and conducted interviews with patients at the PHC facility, in their language of 160 
choice. A structured cost questionnaire was completed detailing the patient’s care-seeking visits 161 
from the reported onset of symptoms to MDR-TB treatment initiation. This included time spent 162 
at healthcare facilities, travel time and out of pocket payments. Employment status and 163 
individual and household income were assessed both prior to the onset of symptoms and at the 164 
time of the interview. The clinical coordinator checked the questionnaire and the text relating to 165 
care seeking visits and transcribed data onto a coded spreadsheet.  166 
 167 
Costs Assessed: 168 
 169 
Direct costs comprised medical (for private practitioner consultation, diagnostic tests and 170 
medication) and non-medical (travel for return trips to the healthcare provider) expenditure as 171 
reported by patients. Money spent on food and expenditure incurred for persons accompanying 172 
the patient were not assessed. Indirect costs comprised opportunity costs for patient time. The 173 
number of healthcare visits was determined from the folder review and patient interview. 174 
Patient time comprised time spent in a healthcare facility, 8 hours per day for hospitalized 175 
patients, and time spent in travel to the healthcare facility. The cost per hour for patient time 176 
was calculated for all patients using the hourly wage (ZAR11.17) of a municipal worker in Cape 177 
Town in 2013(24). We decided to use a basic wage for all patients as it was difficult to calculate 178 
an average hourly wage for the large percentage that were unemployed or self-employed and 179 
worked variable hours. The implications of this method are addressed in the discussion.  180 
 181 
The total cost to the patient was calculated as the sum of direct and indirect costs. All costs were 182 
calculated in local currency (ZAR) for that year, adjusted to 2013 costs using the annual 183 
consumer price index(25) and converted to US$ based on average United Nations treasury 184 
operational rates in 2013(26). 185 
 186 
Definitions: 187 
 7 
 188 
Healthcare visit: Any visit made to a pharmacy, private practitioner, traditional healer or 189 
medical facility to seek care from the reported onset of symptoms with the current illness to 190 
MDR-TB treatment initiation. This included directly observed therapy (DOT) visits for those on 191 
1st-line TB treatment prior to MDR-TB treatment initiation; non TB-related visits were excluded.  192 
MDR-TB diagnostic time-point: Defined as either pre-treatment, for a presumptive TB case 193 
being concurrently evaluated for TB and drug resistance, or as on 1st line TB treatment, for a 194 
case on a failing 1st-line TB regimen being evaluated for drug susceptibility.   195 
 196 
Data Management and Statistical analysis: 197 
 198 
Data from the case report forms and cost questionnaire were double entered into a Microsoft 199 
SQL database, corrected and analyzed using STATA 12 (StataCorp). Some information on the 200 
variables collected was incomplete and only reported data have been analysed. We compared 201 
differences between the algorithms and between MDR-TB diagnostic time points. Categorical 202 
data were summarized using proportions and compared using the chi-square test. Continuous 203 
data were summarized using means and standard deviations or medians and interquartile 204 
ranges. Continuous variables were assessed using either the two-sample t-test or Wilcoxon rank 205 
sum test depending on the distribution of the variable. 206 
 207 
Median as opposed to mean visits and costs are presented as the data were skewed and medians 208 
are considered a more representative reflection of the sample. Mean values are presented as 209 
supplementary information. We used a quantile regression model to assess the effect of potential 210 
confounders such as age, gender, previous TB and HIV status on median visits and costs. 211 
 212 
Ethics:  213 
 214 
The Health Research Ethics Committee at Stellenbosch University (IRB0005239)(N10/09/308) 215 
and Ethics Advisory Group at The International Union Against Tuberculosis and Lung Disease 216 
(59/10) approved the study. The City Health Directorate, Western Cape Health Department and 217 
National Health Laboratory Service granted permission to use routine health data for which a 218 
waiver of informed consent was granted. All study participants provided informed consent for 219 
interviews.  220 
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 221 
RESULTS  222 
 223 
Demographic and clinical characteristics: 224 
 225 
Of the 226 eligible patients, 153 were interviewed and 73 were excluded (Figure 2). Excluded 226 
patients did not differ significantly in gender (p=0.344), age (p=0.561), HIV status (p=0.893), 227 
previous TB treatment (p=0.101), or MDR-TB diagnostic time-point (p=0.471) from those 228 
included. 229 
 230 
Demographic and clinical data are presented in Table 1 for the 89 patients in the LPA and 64 in 231 
the Xpert groups. There were no significant differences in sex, age, HIV status, and previous TB 232 
treatment between the groups. The majority of patients were diagnosed at the pre-treatment 233 
diagnostic time-point in both groups. The median household size was smaller in the LPA than the 234 
Xpert group (p=0.001). 235 
 236 
Healthcare visits from the start of illness to MDR-TB treatment initiation: 237 
 238 
The median number of health visits to MDR-TB treatment initiation was reduced from 20 in the 239 
LPA group to 7 in the Xpert group (p<0.001) (Table 2). For those diagnosed at the pre-treatment 240 
diagnostic time-point, the median number of visits was reduced from 16 in the LPA group to 6 in 241 
the Xpert group (p<0.001). There were no significant differences between the groups for those 242 
diagnosed whilst on 1st-line TB treatment (p=0.375). 243 
 244 
In the quantile regression model (Table 3), age, gender, HIV status and previous TB were not 245 
significantly associated with the number of visits. When adjusting for these potential 246 
confounders, there were 12 (95% CI 3 to 21, p=0.009) fewer visits in the Xpert group. Cases 247 
diagnosed at the pre-treatment diagnostic time-point had 10 fewer visits (95% CI 4 to 15, 248 
p>0.001) in the Xpert group. For those diagnosed whilst on 1st line TB treatment, there was no 249 
significant difference in the number of visits between the groups (p=0.624). 250 
 251 
The proportion of patients who visited a private practitioner was similar, with 30% in the LPA 252 
and 31% in the Xpert group (p=0.905). The proportion hospitalized at some point prior to MDR-253 
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TB treatment initiation was also similar with 19% in both groups (p=0.957). A higher proportion 254 
attended a healthcare facility or a community site for DOT relating to their 1st line TB regimen in 255 
the LPA group (69%) than in the Xpert group (39%) (p<0.001).  256 
 257 
Cost to the patient: 258 
 259 
The total median cost to the patient from the start of the illness to MDR-TB treatment initiation 260 
was reduced from $68.1 (IQR 32.0 to 142.0) in the LPA group to $38.3 (IQR 14.1 to 79.3) in the 261 
Xpert group (p=0.004)(Table 4). Median direct costs were $6.7 (IQR $1.1 to $28.2) in the LPA 262 
group and $4.4 (IQR 0.0 to $22.2) in the Xpert group (p=0.321). Median indirect costs were 263 
reduced from $40.0 (IQR $20.4 to $105.9) in the LPA group to $22.1 (IQR $11.0 to $54.5) in the 264 
Xpert group (p=0.003).  265 
 266 
All patients incurred indirect costs, but only 34 patients in the LPA group and 22 in the Xpert 267 
group incurred direct medical costs with medians of $22.9 (IQR $17.2 to $28.9) and $22.0 (IQR 268 
$15.7 to $26.0) respectively. Direct transport cost were incurred by 66 patients in the LPA group 269 
and 41 in the Xpert group with medians of $5.3 (IQR 2.7 to 8.1) and $4.6 (IQR 1.6 to 10.3) 270 
respectively.  271 
 272 
For those diagnosed at the pre-treatment diagnostic time-point, the total median cost to the 273 
patient was reduced from $49.8 (IQR 23.7 to 96.4) in the LPA group to $29.0 (IQR 12.5 to 57.6) 274 
in the Xpert group (p=0.004). For those diagnosed whilst on 1st line TB treatment the total 275 
median cost to the patient was $167.6 (IQR 105.1 to 273.2) in the LPA group compared to $179.4 276 
(IQR 65.8 to 228.7) in the Xpert group (p=0.531).  277 
 278 
In the quantile regression model (Table 3), gender, HIV status and previous TB were not 279 
significantly associated with costs. When adjusting for these potential confounders, there was a 280 
reduction of $35.4 (95% CI 6.1 to 64.7, p=0.018) in median costs in the Xpert group. Cases 281 
diagnosed at the pre-treatment diagnostic time-point had a reduction of $23.5 (95% CI $1.7 to 282 
$45.2, p>0.035) in the Xpert group. There was no significant difference in costs between the 283 
groups (p=0.583) for those diagnosed whilst on 1st line TB treatment. Costs for those diagnosed 284 
on 1st line TB treatment were $102.6 higher (p<0.001) in LPA group and $147.9 higher in the 285 
Xpert group compared to those diagnosed pre-treatment in each group.  286 
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 287 
Change in employment status: 288 
 289 
From the start of their illness to being interviewed the proportion unemployed increased from 290 
39% to 73% in the LPA group (p<0.001) and from 53% to 89% in the Xpert group (p<0.001) 291 
(Table 5). In the LPA group 36% lost employment after the start of their illness compared to 292 
27% in the Xpert group (p=0.222); 94% in both groups reported this to be directly attributable 293 
to having contracted MDR–TB. Both patients who stopped schooling or tertiary education in the 294 
LPA group and 6 of the 7 in the Xpert group reported this as attributable to MDR-TB. 295 
 296 
Change in individual and household income:  297 
 298 
In the LPA group 58% earned an income from employment prior to MDR-TB illness compared to 299 
36% in the Xpert group. Of those earning an income, 67% in the LPA group and 65% in the Xpert 300 
group lost income between the start of their illness and MDR-TB treatment initiation (Table 5). 301 
 302 
Prior to their illness 20 (22%) patients in the LPA group and 17 (27%) in the Xpert group 303 
received money from a social grant, of which 1 in the LPA group and 5 in the Xpert group 304 
comprised a temporary or permanent disability grant (Table 5). At the time of the interview an 305 
additional 36 (40%) in the LPA group and 14 (22%) in the Xpert group (p=0.016) received 306 
temporary disability grants, linked to their illness. 307 
 308 
In both groups 97% knew or could estimate their monthly household income with 38% in the 309 
LPA group and 27% in the Xpert group losing >10% of monthly household income between the 310 
start of their illness and time of the interview (Table 5). Overall there was a 16% decrease in 311 
median household income in the LPA group compared to 13% in the Xpert group.   312 
 313 
DISCUSSION 314 
 315 
This study compared costs incurred by MDR-TB patients in an existing LPA-based diagnostic 316 
algorithm to that in a newly introduced Xpert-based algorithm from the reported onset of 317 
symptoms to MDR-TB treatment initiation. The number of health- visits (and thus costs) was 318 
expected to decrease in the Xpert-based algorithm for two reasons: firstly, Xpert provided a 319 
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quicker DST result than LPA (median <1 day compared to 24 days to a result being available in 320 
the laboratory(19)), thus fewer patients would be started on 1st line TB treatment whilst 321 
awaiting a DST result. Secondly, all presumptive TB cases would be simultaneously screened for 322 
TB and drug susceptibility in the Xpert group; in comparison, those at low risk of MDR-TB in the 323 
LPA group were only evaluated for drug susceptibility when 1st line TB treatment failed (usually 324 
after 2-3 months of treatment). An algorithm where all presumptive cases are tested for drug 325 
resistance, irrespective of the test used, will decrease the number of pre-treatment visits by 326 
earlier identification of drug resistance for many patients. 327 
 328 
The introduction of the Xpert-based algorithm decreased the number of pre-treatment 329 
healthcare visits from a median of 20 in the LPA group to 7 in the Xpert group. However, the 330 
number of visits remains high, especially for patients diagnosed whilst on 1st-line TB treatment. 331 
A large contributor to this was DOT visits whilst awaiting a DST result. Visits to private 332 
practitioners (similar in both algorithms) and to health centers not offering TB treatment 333 
increased the number of pre-treatment visits as patients often made several visits, were not 334 
appropriately tested and had to eventually be referred for MDR-TB tests and or treatment. 335 
 336 
There was a significant decrease in median costs for patients in the Xpert ($38.3) compared to 337 
the LPA group ($68.1). As direct medical costs were similar in both groups (all related to private 338 
sector care as public sector services are free) and travel costs were low, this was largely 339 
attributable to indirect costs related to time spent in travel and at the healthcare facility. Other 340 
TB costing studies have also found higher indirect than direct costs (17,18).  341 
 342 
Improved health system efficiencies with the Xpert-based algorithm can help to further reduce 343 
indirect costs. To achieve this, healthcare professionals need to adhere to the testing algorithm 344 
and health delivery issues such leaking sputum containers, broken fax machines, and mislaid 345 
results need to be minimized to eliminate unnecessary pre-treatment visits.  346 
 347 
Other studies have found income loss to be the largest financial burden faced by patients 348 
contracting TB(14).  We found a high proportion of patients, in both algorithms, who lost income 349 
as a result of employment loss due to their illness, highlighting the devastating impact MDR-TB 350 
can have on a patient’s livelihood, irrespective of the speed at which they are diagnosed. Studies 351 
are needed to ascertain if people regain employment, once they have commenced or completed 352 
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treatment, however with the poor treatment outcomes for MDR-TB (27) this is likely to be low. 353 
There was a marked loss of monthly household income in both groups. “Catastrophic” costs (14) 354 
were experienced by 38% in the LPA group and 27% in the Xpert group who lost >10% of 355 
monthly household income. 356 
 357 
When estimating costs, different approaches may influence the cost estimate. In this study 358 
indirect costs for patient’s time were calculated for all patients based on a basic municipal 359 
workers wage. This may have overestimated indirect costs for those unemployed, although this 360 
effect may be counter-balanced, as the study did not cost unpaid work in the household and the 361 
cost to the unemployed who lost time that could have been used to seek new employment.  362 
 363 
There are also alternative methods of calculating indirect costs – we have used the traditional 364 
human capital method, which assumes a loss equivalent to the production that could have 365 
occurred in the time foregone, using hourly wages to value this production(28). Alternative 366 
methods, such as the friction cost approach(29) assume some reorganization to minimize 367 
disruption (e.g. individuals substituting leisure time for paid or unpaid work). Our approach may 368 
therefore overstate indirect costs by not accounting for such flexibility, although it is not possible 369 
to quantify the impact of this. 370 
 371 
Strengths and Limitations: 372 
 373 
As patients were interviewed 3 to 6 months after the start of MDR-TB treatment, recall bias may 374 
have influenced findings. A strength of our study was that was that we were able to triangulate 375 
visit data from patient interviews with clinical records which is likely to have reduced reporting 376 
bias.  377 
 378 
However, the study had limitations. Firstly, this was an observational study conducted in routine 379 
operational conditions. Temporal changes such as the full decentralisation of MDR-TB treatment 380 
may have contributed to the findings. Secondly, the patients sampled were not representative of 381 
all MDR-TB patients. Untreated patients were not included. To reduce the risk of infection to 382 
researchers, only patients who had been on MDR-TB treatment for at least 3 months and had 383 
smear-converted were interviewed. Patients who were lost to follow-up, which may have been 384 
influenced by the high cost of illness, or had failed to smear convert were not included. Healthier 385 
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people were thus more likely to be interviewed, which may have underestimated costs, but this 386 
is unlikely to have been different between the two algorithms.  387 
 388 
Thirdly, we did not assess coping strategies that patients may have resorted to such as the sale of 389 
assets and borrowing. Lastly, we have not assessed visits or costs based on clinic performance as 390 
the clinic ranking changed each year and the number of patients was too small. The study 391 
included the early phase of Xpert implementation, which may have increased the median 392 
number of pre-treatment visits in the Xpert group as staff became familiar with the new 393 
algorithm and new practices were entrenched.  394 
 395 
Implications of Study Findings: 396 
 397 
Given the high loss of employment attributable to their having developed MDR-TB, many of 398 
these patients and their households are in need of financial support. There have been 399 
international calls by the World Health Organisation and International Labour Office for 400 
countries to invest in social protection mechanisms such as income replacement and social 401 
support for those affected by illness(30).  402 
 403 
Although disability grants (monthly value $129.2) are available to support MDR-TB patients and 404 
offer a measure of income replacement, access to these was poor with fewer patients receiving a 405 
disability grant at the time of the interview in the Xpert (22%) compared to the LPA group 406 
(40%). This may reflect the time it takes to process a grant, with this not yet having taken place 407 
for those diagnosed in the Xpert-based algorithm. Expedited access to disability grants is 408 
required: the provision of unconditional disability grants could be considered for diseases such 409 
as MDR-TB as the means-testing process (undertaken by a doctor) contributes to delay. On a 410 
positive note, the low direct medical costs incurred by patients bare testimony to the social 411 
protection offered by free public health services in South Africa.  412 
 413 
CONCLUSION 414 
 415 
Assessing the economic relief to the patient and their household is important in understanding 416 
the impact of new molecular TB diagnostics. This study has shown that the introduction of an 417 
Xpert-based algorithm brought relief by decreasing the costs incurred by patients, mostly by 418 
 14 
reducing the number of visits to treatment initiation. Improved health service efficiencies can 419 
help further reduce costs. 420 
 421 
The link between TB and poverty is strong (1,31). In our setting, even though MDR-TB diagnosis 422 
and treatment are free and easily accessible, the economic impact of MDR-TB was large, with 423 
many patients losing employment and individual and household income. It is important for 424 
health planners to be cognizant of the fact that irrespective of how quickly treatment is initiated 425 
with a rapid MDR-TB test, a high number of patients will be vulnerable to the effects of increased 426 
poverty. Efforts need to be made to mitigate this to break the poverty-illness cycle. 427 
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 510 
Table 1: Demographic, Socioeconomic and Clinical Characteristics of Study Patients 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
1Education level was missing for one patient in the Xpert group.  538 
Abbreviations: LPA= MDRTBPlus line probe assay; Xpert = Xpert MTB/RIF; SD= Standard Deviation; HIV=Human 539 
Immunodeficiency Virus; TB=Tuberculosis; MDR-TB= Multidrug Resistant Tuberculosis; IQR= Interquartile Range 540 
541 
Variable LPA Group 
(n=89) 
Xpert Group  
(n=64) 
p-value 
Sex, Female (number, %) 44 (49%) 27 (42%) p=0.375 
Mean Age, years  
SD 
(Range) 
36.8 
10.7 
(19-70) 
35 .3 
9.7 
(19-63) 
p=0.300 
HIV-positive (number, %) 57 (64%) 34 (53%) p=0.175 
Previous TB treatment (number, %) 45 (51%) 30 (47%) p=0.653 
MDR-TB diagnostic time-point: Pre-treatment (number, %) 74 (83%) 55 (86%) p=0.640 
Highest Education level attained1 (number, %) 
 No education 
 Primary school education (Grade 1-Grade 7) 
 Some high school education (Gr 8- Grade 11) 
 Completed high school education (Grade 12) 
 Tertiary education 
 
2   (2%) 
29 (33%) 
44 (49%) 
13 (15%) 
1   (1%) 
 
0   (0%) 
15 (24%) 
36 (57%) 
7   (11%) 
5   (8%) 
p =0.112
Median number of people in household                                                               
IQR 
3 
2-4 
4 
3-5.5 
p=0.001 
Median number of dependents                                                    
IQR 
2 
1-3 
1 
0-2.5 
p=0.278 
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Table 2: Median Number of Healthcare Visits in the LPA and Xpert Groups 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
The table shows unadjusted data. Healthcare visits include all visits to both the public and private health sector. Visits 558 
for directly observed therapy (DOT) are included for patients on a 1st line TB regimen, either whilst awaiting drug 559 
susceptibility test results or for those who were not evaluated when diagnosed with TB. Only 1.4% of visits in the LPA 560 
group and 3.2% in the Xpert group were to the private sector. 561 
Abbreviations: LPA = MDRTBPlus line probe assay; Xpert = Xpert MTB/RIF; TB = Tuberculosis; IQR = Interquartile 562 
Range; Min-Max = Minimum – Maximum 563 
Data on mean visits are presented in supplemental information. 564 
 565 
566 
 
Median IQR Min-Max p-value 
LPA Group - all patients  
(n=89)  
20 10-44 2-171 p<0.001 
Xpert Group - all patients  
(n=64)   
7 4-23 2-184 
LPA Group – pre-treatment  
(n=74) 
16 7-28 2-164 p<0.001 
Xpert Group –pre-treatment 
(n=55)   
6 4-12 2-73 
LPA Group – on 1st line TB treatment 
(n=15)   
77 48-126 25-171 p=0.375 
Xpert Group -  on 1st line TB treatment  
(n=9) 
51 46-77 19-184 
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Table 3: Quantile Regression Model Outputs for Number of Healthcare Visits and Patient Costs 567 
 568 Variable Coefficient Standard Error p-value 95% Confidence 
Interval Adjusted Data for Number of Healthcare Visits – All patients 
Xpert Group -11.9 4.5 0.009 -20.8 to -3.1 
Gender 5.4 4.5 0.224 -3.4 to 14.3 
HIV status -0.9 4.5 0.843 -9.8 to 8.0 
Age -0.1 0.2 0.742 -0.5 to 0.4 
Previous TB -0.4 4.4 0.921 -9.2 to 8.3 
Constant 20.8 9.2 0.026 2.5 to 39.1 
Adjusted Data for Number of Healthcare Visits –  Patients at Pre-treatment Diagnostic Time 
Point 
Adjusted Visit Data – All patients 
Adjusted Visit Data – All patients 
Adjusted Visit Data – All patients 
Adjusted Visit Data – All patients 
Xper  Group -9.6 2.7 0.001 -14.9 to -4.2 
Gender 2.3 2.7 0.401 -3.1 to 7.6 
HIV status -0.1 2.7 0.979 -5.4 to 5.3 
Age -0.1 0.1 0.524 -0.4 to 0.2 
Previous TB 1.8 2.7 0.509 -3.5 to 7.1 
Constant 17.2 5.8 0.004 5.6 to 28.7 
Adjusted Data for Number of Healthcare Visits – Patients at Treatment Diagnostic Time Point 
Xpert Group -13.4 26.8 0.624 -69.8 to 43.0 
Gender 16.6 24.7 0.510 -35.3 to 68.5 
HIV status 15.7 25.4 0.545 -37.7 to 69.2 
Age -0.9 1.1 0.405 -3.3 to 1.4 
Previous TB 57.9 35.2 0.117 -16.0 to 131.8 
Constant 88.7 42.2 0.050 0.1 to 177.3 
Adjusted Patient Cost Data ($) – All patients 
Xpert Group -35.4 14.8 0.018 -64.7 to -6.1 
Gender 9.4 14.7 0.524 -19.7 to 38.5 
Previous TB -15.2 14.6 0.298 -44.0 to 13.6 
HIV status -0.7 15.0 0.962 -30.4 to 28.9 
Constant 74.3 16.5 <0.001 41.7 to 107.0 
Adjusted Patient Cost Data ($) –  Patients at Pre-treatment Diagnostic Time Point 
Adjusted Visit Data – All patients 
Adjusted Visit Data – All patients 
Adjusted Visit Data – All patients 
Adjusted Visit Data – All patients 
Xpert Group -23.5 11.0 0.035 -45.2 to -1.7 
Gender 7.3 10.9 0.506 -14.3 to 28.8 
Previous TB 1.9 10.8 0865 -19.6 to 23.3 
HIV status -1.7 11.1 0.880 -23.6 to 20.3 
Constant 48.8 12.9 <0.001 23.2 to 74.3 
Adjusted Patient Cost Data ($)– Patients at Treatment Diagnostic Time Point 
Xpert Group -55.4 99.1 0.583 -262.8 to 152.1 
Gender 48.8 90.3 0.595 -140.3 to 237.9 
Previous TB 114.1 130.2 0.392 -158.4 to 386.5 
HIV status 3.4 92.7 0.972 -190.7 to 197.4 
Constant 121.2 86.8 0.179 -60.5 to 302.9 
Adjusted Cost Comparison at the different Diagnostic Time Points in the LPA-based Algorithm    
Pre-treatment 102.6 25.0 <0.001 52.8 to 152.4 
Constant 69.2 21.3 0.002 26.8 to 111.6 
Adjusted Cost Comparison at the different Diagnostic Time Points in the Xpert-based 
Algorithm    Pre-t eat ent 147.9 24.3 <0.001 99.3 to 196.5 
Constant 14.6 15.5 0.349 -16.4 to 45.6 
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Table 4:  Median Patients Costs in the LPA and Xpert Groups 569 
Costs and time associated with seeking help were calculated from the onset of illness to MDR-TB treatment initiation in South African Rands, adjusted to 2013 values 570 
based on the consumer price index, and converted to US$ at a rate of 9.75 (average United Nations Treasury operational rates in 2013). The total cost to the patient is 571 
the sum of the direct and indirect costs. 572 
The table shows data for all patients in both groups. However, only 67patients in the LPA group and 45 in the Xpert group incurred direct costs with medians of $20.5 573 
(IQR 5.0 to 30.3) and $12.4 (IQR $3.4 to $30.4) respectively. Direct medical costs were incurred by 34 patients in the LPA group and 22 in the Xpert group with median 574 
costs of $22.9 (IQR $17.2 to $28.9) and $22.0 (IQR $15.7 to $26.0) respectively. Direct transport cost were incurred by 66 patients in the LPA group and 41 in the Xpert 575 
group with median costs of $5.3 (IQR 2.7 -8.1) and $4.6 (IQR 1.6-10.3) respectively. 576 
Abbreviations: LPA = MDRTBPlus line probe assay; Xpert = Xpert MTB/RIF; IQR = Interquartile Range 577 
Mean costs are presented as supplemental information. 578 
  n Median Direct Costs ($) 
(IQR) 
 
Median Indirect Costs ($) 
(IQR) 
Median Total Cost to 
Patient 
(IQR)  
p-value     Transport 
Costs  
Medical 
Costs  
Direct Costs 
p-value 
Cost of 
Transport 
Time 
Cost of Time 
in Health 
Facility 
Indirect Costs 
p-value 
LPA Group – 
all patients  
89 3.4 0 6.7 p=0.321 12.3 23.7 40.0 p=0.003 68.1 p=0.004 
(0-6.9) (0-18.1) (1.1-28.2) (6.2-29.6) (11.7-64.4) (20.4-105.9) (32.0-142.0) 
Xpert Group – 
all patients 
64 1.5 0 4.4 4.6 13.4 22.1 38.3 
(0-6.5) (0-16.0) (0.0-22.2) (2.6-14.3) (8.2-39.0) (11.0-54.5) (14.1-79.3) 
LPA Group –  
Pre-treatment  
74 3.2 0 6.5 p=0.345 9.9 19.9 33.7 p=0.005 49.8 p=0.004 
(0-6.9) (0-18.1) (1.1-25.9) (5.8-23.2 (8.9-46.1) (17.5-87.1) (23.7-96.4) 
Xpert Group –  
Pre-treatment 
55 1.5 0 4.2 4.0 12.1 17.3 29.0 
(0-6.5) (0-15.7) (0.0-20.3) (2.5-9.9) (7.3-30.3) (10.9-46.7) (12.5-57.6) 
LPA Group -  
on 1st line TB 
treatment   
15 4.5 0 27.5 p=0.928 54.8 86.4 164.7 p=0.297 167.6 p= 0.531 
(0-6.2) (0-24.1) (0.0-30.0) (30.1-91.2) (31.9-117.0) (76.1-234.5) (105.1-273.2) 
Xpert Group -  
on 1st line TB 
treatment 
9 3.4 0 4.6 25.4 37.0 61.3 179.4 
(0-21.7) (0-22.9) (0.0-44.6) (21.6-46.9) (19.1-155.6) (46.7-202.4) (65.8-228.7) 
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Table 5: A Comparison of Employment Status and Individual and Household Income  579 
 580 
 LPA Group 
(n = 89) 
Xpert Group 
(n = 64) 
p-value 
Number unemployed prior to illness (%) 35 (39%) 34 (53%) p=0.091 
Number unemployed at time of interview (%) 65 (73%) 57 (89%) p=0.015 
Median monthly income from salary prior to illness amongst 
employed ($) (IQR)1  
228.9 
(153.4-330.9) 
265.6 
(194.7-303.6) 
p=0.628 
Median loss of monthly income from salary from start of 
illness to time of interview amongst employed ($) (IQR) 
224.4 
(144.2-320.5) 
251.9 
(160.3-303.6) 
p=0.719 
Of those receiving a grant pre-illness: number receiving 
money from a disability grant (%) 
1 (1%) 5 (8%) - 
Additional number receiving money from a disability grant  
at time of interview (not including those above) 2  
36 (40%) 14 (22%) p=0.016 
Number receiving money from any grant pre-illness (as % of 
total) 
20 (22%) 17 (27%) p=0.560 
Median monthly grant amount ($) pre-illness  
(IQR) 
32.4 
(30.9-80.5) 
60.7 
(30.4-137.3) 
p=0.298 
Median monthly additional grant amount at the time of the 
interview($)3 
(IQR) 
123.6 
(121.4-125.9) 
126.6 
(123.1-130.1) 
p=0.593 
Median monthly household income from all sources prior to 
illness ($) 
(IQR)  
259.3 
(130.5-427.9) 
n = 86 
356.6 
(130.5-618.2) 
n = 62 
p=0.057 
Median monthly household income from all sources at time 
of interview ($) 
(IQR)  
216.8 
(123.6-343.5) 
n = 86 
308.9 
(130.1-471.6) 
n = 60 
p=0.043 
Number of households losing monthly household income 
after becoming ill (reported at time of interview) (%)4 
33 (38%) 
n = 86 
17 (27%) 
n = 62 
p=0.165 
Where data was incomplete or refers to a subset, we specify the denominator as:  n = number reported. 581 
All income or loss thereof was recorded in South African Rands, adjusted to 2013 values based on CPI, and converted to 582 
US$ at a rate of 9.75 (average United Nations Treasury operational rates in 2013 ). 583 
152 patients in the LPA and 23 patients in the Xpert group earned an income from their occupation prior to the start of 584 
illness and 52 in the LPA and 22 in the Xpert groups were able to report their income. 585 
2 19 previously employed patients in the LPA group and 4 in the Xpert group received a monthly disability grant of 586 
$129.2 587 
3Additional grants were all temporary disability grants linked to their illness.  588 
4All households losing income lost >10% of monthly household income. 589 
Abbreviations: LPA = MDRTBPlus line probe assay; Xpert = Xpert MTB/RIF; IQR = Interquartile Range; MDR-TB = 590 
Multidrug Resistant Tuberculosis. 591 
 592 
 593 
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 Figure 1: Testing in the LPA and Xpert-based TB Diagnostic Algorithms 
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Figure 2: Study Population 
 
 
 
Cases identified from 
laboratory and clinic records  
n=360 
 
Eligible patients 
n=226 
Not eligible N=134 
Reasons: 
<18 years old: 5 
Extra-pulmonary TB: 3 
Previous MDR-TB: 3 
No diagnostic result / diagnosed outside 
of Cape Town: 3 
Pre or XDR-TB: 41 
No record MDR-TB treatment: 19 
Interrupted MDR-TB treatment / died: 60 
 
 
Included - Interviewed 
n=153 
 
Excluded - Not interviewed:  N=73 
Reasons: 
Patient too ill / in hospital / still smear 
positive: 38 
Transferred/moved out of area: 6 
Declined interview: 1 
In prison: 2 
Unable to schedule interview: 25 
Unable to do interview due to poor patient 
recall: 1 
 
LPA-Group: 
n=89 
 
Xpert-Group  
n=64 
